# Capstan Medical

> Capstan Medical is a Santa Cruz, California medical device company building a robotic, catheter-based platform to repair and replace heart valves through minimally invasive procedures. By merging surgical robotics, catheter-based delivery, and next-generation implants, the company aims to bring structural heart intervention - starting with mitral and tricuspid valve regurgitation - to patients who are too sick or too high-risk for open-heart surgery. Founded in 2020 and led by CEO Maggie Nixon, Capstan has raised more than $140 million and completed its first robot-assisted transcatheter mitral valve replacements in humans.

- **Founded:** 2020
- **Headquarters:** Santa Cruz, California, United States
- **Founders:** Dan Wallace (Founder), Maggie Nixon (CEO (co-founder / founding leadership))
- **Team size:** Approximately 85 employees
- **Products:** Robotic delivery platform, Mitral valve replacement implant, Tricuspid valve replacement implant
- **Notable:** Completed first-in-human robot-assisted transcatheter mitral valve replacements, treating two patients - a first in structural heart disease treatment., Raised an oversubscribed $110 million Series C in December 2024, bringing total funding to more than $140 million., Recognized as a Santa Cruz Works 'Titan' for its pioneering robotic heart valve procedure.

## Products & services

- **Robotic delivery platform** — A proprietary, catheter-based robotic system - described as the first of its kind - that delivers and positions heart valve implants with precision inside the beating heart.
- **Mitral valve replacement implant** — A next-generation transcatheter implant designed to treat mitral valve regurgitation, where the mitral valve fails to close properly and allows blood to flow backward.
- **Tricuspid valve replacement implant** — An implant program for tricuspid valve regurgitation that leverages the same robotic delivery platform as the mitral program.

## Achievements

- Completed first-in-human robot-assisted transcatheter mitral valve replacements, treating two patients - a first in structural heart disease treatment.
- Raised an oversubscribed $110 million Series C in December 2024, bringing total funding to more than $140 million.
- Recognized as a Santa Cruz Works 'Titan' for its pioneering robotic heart valve procedure.
- Built a single robotic platform that supports both mitral and tricuspid valve programs.

## Latest updates

- **2024-12** — Closed an oversubscribed $110M Series C led by Eclipse, with Intuitive Ventures, Yu Galaxy, and Gideon Strategic Partners participating; total funding surpasses $140M.
- **2025-01** — Announced first-in-human robot-assisted transcatheter mitral valve replacements in two patients.
- **2025-01** — Tricuspid replacement implant moving into full development in preparation for first-in-human trials, using the same robotic platform; pivotal trials targeted for 2026.

## Links

- Website: https://capstanmedical.com
- LinkedIn: http://www.linkedin.com/company/capstanmedical

---

Profile page: https://yespress.io/capstan-medical
Published by YesPress — https://yespress.io
Last updated: 2026-06-15